Clinical trials: Androgens
Prostate Cancer
Ixabepilone With or Without Estramustine in Treating Patients With Progressive Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as ixabepilone and estramustine, use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00025194
- Testing
- estramustine phosphate sodium, ixabepilone
- Where
- 4 sites in United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
This phase II trial studies the effect of androgen ablation therapy with or without niraparib after standard of care radiation therapy in treating patients with prostate cancer that has not spread to other parts of the body…
- Conditions
- Prostate Carcinoma, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8
- Trial name
- NCT04947254
- Testing
- Abiraterone Acetate, Antiandrogen Therapy, Apalutamide
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Transdermal Estradiol and Exercise in Mitigating Adverse Effects of Androgen Deprivation Therapy for Prostate Cancer Radiation Therapy
The goal of the clinical trial is to find out whether transdermal estradiol will reduce the adverse effects of androgen deprivation therapy in prostate cancer patients.
- Trial name
- ESTRACISE (NCT06271551)
- Testing
- Transdermal estrogen, Active Comparator: Androgen deprivation therapy, Resistance training
- Volunteers
- 310 people
- Sponsor
- Central Finland Hospital District
Autism
Effects of Metformin on Androgens and Other Steroid Hormones in Affected Subjects With Autism
Autism is diagnosed with increasing frequency in recent years despite remaining uncertainty concerning the cause. The disorder is characterized by deficits in social behavior, a lack of communication skills, and repetitive and…
- Trial name
- Metformin (NCT06762041)
- Testing
- Metformin treatment
- Volunteers
- 20 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Metastatic Hormone-sensitive Prostate Cancer
Darolutamide in Addition to Standard Androgen Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer
The purpose of the study is to assess the efficacy and safety of BAY1841788 (darolutamide (ODM-201)) in combination with standard androgen deprivation therapy (ADT) and docetaxel in patients with metastatic hormone sensitive…
- Trial name
- ARASENS (NCT02799602)
- Testing
- BAY1841788 / darolutamide (ODM-201), Standard ADT (androgen deprivation therapy), Docetaxel
- Where
- 322 sites in United States, Australia and 21 more
- Volunteers
- 1,306 people
- Sponsor
- Bayer
Prostate Adenocarcinoma, Metastatic Prostate Adenocarcinoma
Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC)
This is a single-arm, multicenter open label, international, phase II study of Bipolar Androgen Therapy (BAT) plus Radium-223 (RAD) in men with metastatic castration-resistant prostate cancer (mCRPC).
- Conditions
- Prostate Adenocarcinoma, Metastatic Prostate Adenocarcinoma, Castration-resistant
- Trial name
- BAT-RAD (NCT04704505)
- Testing
- radium-223, Bipolar Androgen Therapy (BAT)
- Where
- 2 sites in United States, Brazil
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer
ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer
The purpose of this study is to evaluate whether treatment with a new drug called ZK-Epothilone (ZK-Epo) given with prednisone in patients with androgen-independent prostate cancer, who have not had previous chemotherapy, is safe…
- Trial name
- NCT00350051
- Testing
- Sagopilone (ZK 219477) + prednisone
- Where
- 17 sites in United States, Argentina
- Volunteers
- 53 people
- Sponsor
- Bayer
COVID-19, SARS-CoV2
Anti-Androgen Treatment for COVID-19
This study is intended to explore the possible protective role of anti-androgens in SARS-CoV-2 infection
- Conditions
- COVID-19, SARS-CoV2, Androgenetic Alopecia, Prostate Cancer
- Trial name
- NCT04446429
- Testing
- Proxalutamide, Standard of Care
- Where
- Brazil
- Volunteers
- 268 people
- Sponsor
- Applied Biology, Inc.
Cancer of Prostate
Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP
This is a phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of androgen-deprivation therapy (ADT) with LHRH agonist or antagonist (arm A) versus anti-androgen therapy (AAT) with…
- Trial name
- SAVE (NCT03899077)
- Testing
- Apalutamide, Leuprorelin Acetate 45Mg Powder for Injection Suspension Vial, Goserelin Acetate 10.8 MG Subcutaneous Implant
- Where
- 9 sites in Belgium
- Volunteers
- 202 people
- Sponsor
- Cancer Research Antwerp
Triple-Negative Breast Cancer
T-DXd in the First-Line Treatment of Locally Advanced or Metastatic TNBC-LAR HER2-low Patients
This is an open-label, single-arm phase II trial of first-line treatment with trastuzumab deruxtecan (T-DXd) for patients with locally advanced or metastatic triple-negative breast cancer, luminal androgen receptor subtype…
- Trial name
- NCT05953168
- Testing
- Trastuzumab Deruxtecan
- Where
- China
- Volunteers
- 69 people
- Sponsor
- Fudan University
Urogenital Abnormalities, Prenatal Disorder
Fetal Ano-genital Distance in 2D Ultrasound.
The purpose of this study is to determine a threshold value of fetal anogenital distance in 2D ultrasound to differentiate male fetuses from female fetuses, starting 18 weeks of gestation and until the due date.
- Conditions
- Urogenital Abnormalities, Prenatal Disorder, Sex Development Disorder
- Trial name
- DAG (NCT03898440)
- Where
- France
- Volunteers
- 318 people, healthy volunteers welcome
- Sponsor
- University Hospital, Brest
Metastatic Prostate Cancer
CMAB vs IMAB in Metastatic Prostate Cancer
To evaluate the efficacy, safety and survival of two treatment regimens: Continuous Intermittent Maximum Androgen Blockade, using goserelin and bicalutamide in patients with prostate cancer.
- Trial name
- NCT00255268
- Testing
- Goserelin, Bicalutamide
- Where
- 2 sites in Mexico
- Volunteers
- 15 people
- Sponsor
- AstraZeneca
Prostate Cancer
153Sm-EDTMP With or Without a PSA/TRICOM Vaccine To Treat Men With Androgen-Insensitive Prostate Cancer
Background: No treatment is known to improve survival for prostate cancer patients who have not been helped by previous treatments with hormones and chemotherapy.
- Trial name
- NCT00450619
- Testing
- Samarium Sm 153 lexidronam pentasodium, Sargramostim, Recombinant vaccinia-TRICOM vaccine
- Where
- 3 sites in United States
- Volunteers
- 44 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
PET/CT Characterization of Treatment Resistance
This study will use different types of medical imaging to assess how lesions from advanced prostate cancer become resistant to second-generation AR-targeted therapy, and how the different types of imaging compare in that…
- Trial name
- NCT05647564
- Testing
- F-fluorodeoxyglucose positron emission tomography (FDG PET), prostate-specific membrane antigen positron emission tomography (PSMA PET)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Wisconsin, Madison
Telomere Disease
Low-Dose Danazol for the Treatment of Telomere Related Diseases
Background: DNA is a structure in the body. It contains data about how the body develops and works. Telomeres are found on the end of chromosomes in DNA.
- Trial name
- NCT03312400
- Testing
- Danazol
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Sarcopenia
Anabolic and Inflammatory Responses to Short-Term Testosterone Administration in Older Men
Skeletal muscle loss is a common consequence of aging and in some individuals reaches a level that compromises health and quality of life.
- Trial name
- NCT00957801
- Testing
- Testosterone injection, Testosterone gel, Medrol
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Breast Cancer
of Androgen Receptor Expression in Breast Cancer With or Without BRCA Mutation
Androgen Receptor is extensively expressed in BRCA and its role in the disease may differ depending upon molecular subtypes and stages.
- Trial name
- NCT05404334
- Testing
- Androgen receptor status and BRCA mutation
- Where
- India
- Volunteers
- 231 people
- Sponsor
- Banaras Hindu University
Prostate Cancer
Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer
The purpose of this study is to evaluate the safety of a new drug- sorafenib, which is to be administered at the same time as standard treatment, which includes hormonal therapy and external beam radiotherapy.
- Trial name
- NCT00924807
- Testing
- Leuprolide acetate, Bicalutamide, Sorafenib
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Beth Israel Medical Center
Reccurent/Metastatic Solid Tumor Disease, Prostate Cancer (Post Prostatectomy)
Non-inferiority Study Comparing Salvage Pelvic Radiotherapy in 25 Fractions (62.5 Gy/25) Versus 20 Fractions (52.5 Gy/20) for Recurrent Prostate Cancer After Surgery.
Study Overview This research compares two types of post-operative salvage radiotherapy (SRT) for men with prostate cancer who have had surgery but show signs of recurrence (detectable PSA).
- Conditions
- Reccurent/Metastatic Solid Tumor Disease, Prostate Cancer (Post Prostatectomy), Prostate Cancer, Prostatic Neoplasms
- Trial name
- HYP-OP-RT (NCT07483658)
- Testing
- Standard Fractionation Post-Operative Salvage Radiotherapy (25 fractions), Hypofractionated Post-Operative Salvage Radiotherapy (20 fractions), Androgen Deprivation Therapy (ADT)
- Where
- 4 sites in Canada
- Volunteers
- 434 people
- Sponsor
- CHU de Quebec-Universite Laval
Prostate Cancer
Soy Derivatives for Control of Hot Flashes in Men on Androgen Deprivation Therapy
To determine the efficacy of soy/isoflavone supplementation on hot flashes in men who are being treated with luteinizing hormone-releasing hormone (LHRH) agonist therapy for control of advanced prostate cancer
- Trial name
- NCT00594620
- Testing
- Flav-ein capsules
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Kansas Medical Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.